Doxazosin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Doxazosin: From Hypertension to Migraine Disorder
One-Sentence Summary
Doxazosin is a selective alpha-1 adrenergic receptor blocker widely used for the treatment of hypertension and benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Migraine Disorder, placing it at rank 12,265 in the prediction output. Supporting evidence is limited to 0 clinical trials and 1 expert commentary from 1997, making this an early-stage research hypothesis requiring further investigation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension, Benign Prostatic Hyperplasia (BPH) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current Evidence Pack. Based on established pharmacological knowledge, Doxazosin is a selective alpha-1 adrenergic receptor antagonist. By blocking alpha-1 receptors on vascular smooth muscle, it inhibits norepinephrine-driven vasoconstriction, leading to vasodilation and reduced peripheral vascular resistance — the basis of its antihypertensive effect.
The theoretical link to migraine lies in the trigeminovascular system, where cerebrovascular tone (CVT) dysregulation and sympathetic nervous system hyperactivation are implicated in migraine pathophysiology. Alpha-1 receptor blockade could theoretically stabilise cerebrovascular tone, reduce the risk of vasospasm, and attenuate peripheral sensitisation of pain pathways. A 1997 expert commentary by Vatz reported that 9 out of 10 migraine patients placed on either terazosin or doxazosin experienced reduced migraine frequency or severity, lending early observational support to this hypothesis.
However, there are important mechanistic caveats. The established migraine prophylaxis agents in the adrenergic class are beta-blockers (e.g. Propranolol, FDA-approved), not alpha-1 blockers. The role of alpha-1 selective blockade is far less characterised in migraine, and orthostatic hypotension — a known side effect of Doxazosin — could paradoxically trigger or worsen migraine episodes. The risk-benefit balance of this mechanism for migraine remains undefined.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9074296 | 1997 | Expert Commentary / Narrative Review | Headache | 10 migraine patients placed on terazosin or doxazosin; 9 experienced reduced frequency or severity, but 5 discontinued due to side effects. No serious adverse reactions reported. |
India Market Information
Doxazosin is currently not marketed in India and holds no active drug registrations with CDSCO. No licensed products, dosage forms, or approved indications are on record.
Safety Considerations
Drug Interactions (DDI): A total of 185 drug-drug interactions have been identified for Doxazosin. Key interactions of clinical relevance include:
| Interacting Drug | Interaction Level | Notes |
|---|---|---|
| Hydrocortisone | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Prednisolone | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Prednisone | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Dexamethasone | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Betamethasone | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Budesonide | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Triamcinolone | Moderate | Corticosteroids may antagonise the hypotensive effect |
| Morphine | Moderate | Enhanced hypotensive effect; risk of orthostatic hypotension |
| Opium | Moderate | Enhanced hypotensive effect; risk of orthostatic hypotension |
| Bupropion | Moderate | Potential additive CNS/cardiovascular effects |
| Clarithromycin | Moderate | CYP3A4 inhibition may increase Doxazosin plasma levels |
| Canagliflozin | Moderate | Additive blood pressure-lowering effect |
| Dapagliflozin | Moderate | Additive blood pressure-lowering effect |
| Empagliflozin | Moderate | Additive blood pressure-lowering effect |
| Ertugliflozin | Moderate | Additive blood pressure-lowering effect |
| Dronabinol | Moderate | Additive hypotensive effect |
| Nabilone | Moderate | Additive hypotensive effect |
For complete package insert warnings and contraindications, please refer to the official prescribing information.
Conclusion and Next Steps
Decision: Hold
Rationale: The sole piece of direct clinical evidence is a 1997 expert commentary with no control group and a high dropout rate due to adverse effects; no registered clinical trials exist for this indication, and Doxazosin is not currently marketed in India. The mechanistic hypothesis is plausible but significantly weaker than the established beta-blocker evidence base for migraine prophylaxis, and the risk of orthostatic hypotension is a meaningful safety concern in this patient population.
To proceed, the following is needed:
- Retrieval and review of the complete Doxazosin prescribing information (contraindications and warnings) from an established regulatory authority (e.g. FDA, EMA) to complete the S1 safety screen
- Clarification of mechanism of action (alpha-1 receptor subtype selectivity and CNS penetration) to strengthen the mechanistic rationale
- Systematic literature search beyond PubMed to identify any unpublished or grey literature reports
- Design of a prospective observational study or small pilot RCT to generate Phase 2-level clinical evidence before any investment decision is made
- Assessment of the orthostatic hypotension risk profile specifically in migraine patient demographics (often young women of reproductive age)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.